Warning Letter On Adverse Event Reporting May Stem As Much From Jazz Reaction As REMS Problem
This article was originally published in The Pink Sheet Daily
Executive Summary
Jazz Pharmaceuticals initially admitted it had known about 10 deaths and 64 other serious, unexpected adverse drug experiences associated with its cataplexy drug Xyrem, but later changed its story, FDA says.
You may also be interested in...
Adverse Event Reports From Acorda Languished As Long As 100 Days, FDA Finds
FDA warning letter says the company did not report all complaints about the lack of efficacy of its muscular sclerosis drug Ampyra.
Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture
FDA's warning letter to Sanofi-Aventis US over the firm's failure to resolve problems that have delayed adverse event reporting shows the agency is emphasizing the issue in its compliance efforts – and becoming more pointed in its requests for fixes.
Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug
Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.